Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trebananib + liposomal doxorubicin
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Trebananib + liposomal doxorubicin is a combination therapy investigated primarily for the treatment of recurrent epithelial ovarian cancer. Trebananib (AMG 386) is a recombinant peptide-Fc fusion protein that inhibits angiogenesis by blocking the interaction of angiopoietin 1 and 2 with the Tie2 receptor, thereby disrupting blood vessel formation essential for tumor growth[4][5]. Liposomal doxorubicin is an anthracycline chemotherapy agent encapsulated in pegylated liposomes to prolong circulation time and enhance delivery to tumors. Its mechanism involves intercalation into DNA, inhibition of topoisomerase II, and generation of free radicals leading to cell death[6][7][8]. The combination has been studied in phase III clinical trials for recurrent ovarian cancer but did not show significant improvement in progression-free survival compared to monotherapy with pegylated liposomal doxorubicin[4][5].
- Brand names
- Lipodox
- Other names
- pegylated liposomal doxorubicinPLD
02
Targets
ANGPT1 (Angiopoietin-1)ANGPT2 (Angiopoietin-2)DNATEK (Tie2)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on trebananib + liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trebananib + liposomal doxorubicin.